Revenue Insights: Vertex Pharmaceuticals Incorporated and Teva Pharmaceutical Industries Limited Performance Compared

Vertex vs. Teva: A Decade of Revenue Dynamics

__timestampTeva Pharmaceutical Industries LimitedVertex Pharmaceuticals Incorporated
Wednesday, January 1, 201420272000000580415000
Thursday, January 1, 2015196520000001032336000
Friday, January 1, 2016219030000001702177000
Sunday, January 1, 2017223850000002488652000
Monday, January 1, 2018188540000003047597000
Tuesday, January 1, 2019168870000004162821000
Wednesday, January 1, 2020166580000006205683000
Friday, January 1, 2021158780000007574400000
Saturday, January 1, 2022149250000008930700000
Sunday, January 1, 2023158460000009869200000
Monday, January 1, 20241654400000011020100000
Loading chart...

Cracking the code

Revenue Trends in the Pharmaceutical Industry: A Comparative Analysis

In the ever-evolving landscape of the pharmaceutical industry, understanding revenue trends is crucial for investors and stakeholders. This analysis focuses on the performance of Vertex Pharmaceuticals Incorporated and Teva Pharmaceutical Industries Limited from 2014 to 2023. Over this period, Vertex Pharmaceuticals has shown a remarkable growth trajectory, with its revenue increasing by over 1,600%, from approximately $580 million in 2014 to nearly $9.9 billion in 2023. In contrast, Teva Pharmaceutical Industries experienced a decline of about 22% in revenue, from $20.3 billion in 2014 to $15.8 billion in 2023. This divergence highlights Vertex's successful innovation and market expansion, while Teva faces challenges in maintaining its market share. As the pharmaceutical sector continues to adapt to global health demands, these insights provide a window into the strategic shifts shaping the industry's future.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025